Sumatrolide Solution Tablets, 500 mg 3 pcs

Antibiotic of macrolide group, is a representative of azalides. It suppresses RNA-dependent protein synthesis of susceptible microorganisms.

Active against Gram-positive bacteria: Staphylococcus aureus, Streptococcus spp. Streptococcus pneumoniae, Streptococcus pyogenes /group A/); Gram-negative bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus ducreyi, Moraxella catarrhalis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Neisseria gonorrhoeae, Campylobacter spp, Legionella pneumophila; anaerobic bacteria: Bacteroides fragilis.

Azithromycin is also active against Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis, Treponema pallidum.
Active also against Toxoplasma gondii.

Pharmacokinetics

It is quickly absorbed from the gastrointestinal tract. Food intake reduces absorption of azithromycin. Cmax in plasma is reached after 2-3 hours. Rapidly distributed in tissues and body fluids. 35% of azithromycin is metabolized in the liver by demethylation. More than 59% is excreted with bile unchanged, about 4.5% – with urine unchanged.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to azithromycin, incl. bronchitis, pneumonia, skin and soft tissue infections, otitis media, sinusitis, pharyngitis, tonsillitis, gonorrheal and non-gonorrheal urethritis and/or cervicitis, Lyme disease (borreliosis).

Pharmacological effect

An antibiotic of the macrolide group, a representative of the azalides. Suppresses RNA-dependent protein synthesis of sensitive microorganisms.

Active against gram-positive bacteria: Staphylococcus aureus, Streptococcus spp. (including Streptococcus pneumoniae, Streptococcus pyogenes /group A/); gram-negative bacteria: Haemophilus influenzae, Haemophilus parainfluenzae, Haemophilus ducreyi, Moraxella catarrhalis, Escherichia coli, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Neisseria gonorrhoeae, Campylobacter spp., Legionella pneumophila; anaerobic bacteria: Bacteroides fragilis.

Azithromycin is also active against Chlamydia trachomatis, Mycoplasma pneumoniae, Mycoplasma hominis, Treponema pallidum.
Also active against Toxoplasma gondii.

Pharmacokinetics

Rapidly absorbed from the gastrointestinal tract. Eating reduces the absorption of azithromycin. Cmax in plasma is achieved after 2-3 hours. It is quickly distributed in tissues and biological fluids. 35% of azithromycin is metabolized in the liver by demethylation. More than 59% is excreted unchanged in bile, about 4.5% is excreted unchanged in urine.

Special instructions

Not recommended for use in patients with impaired liver function.

Use with caution in case of impaired renal function.

Azithromycin should be taken at least 1 hour before or 2 hours after meals or antacids.

Active ingredient

Azithromycin

Composition

1 tab. contains:

Active substances:

azithromycin (dihydrate form) 500 mg

Excipients:

microcrystalline cellulose,

crospovidone,

pregelatinized starch,

blackcurrant flavoring,

magnesium stearate,

sodium saccharinate,

vanillin,

colloidal silicon dioxide.

Contraindications

Hypersensitivity to azithromycin and other macrolide antibiotics.

Side Effects

From the digestive system: nausea, vomiting, flatulence, diarrhea, abdominal pain, transient increase in the activity of liver enzymes; rarely – cholestatic jaundice.

Allergic reactions: rarely – skin rash, angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Dermatological reactions: rarely – photosensitivity.

From the side of the central nervous system: dizziness, headache; rarely – drowsiness, weakness.

From the hematopoietic system: rarely – leukopenia, neutropenia, thrombocytopenia.

From the cardiovascular system: rarely – chest pain.

From the genitourinary system: vaginitis; rarely – candidiasis, nephritis, increased residual urea nitrogen.

Other: rarely – hyperglycemia, arthralgia.

Interaction

When used simultaneously with ergot alkaloids, the risk of developing ergotism cannot be excluded.

When azithromycin is used simultaneously with warfarin, cases of increased effects of the latter have been described.

With the simultaneous use of digoxin or digitoxin with azithromycin, a significant increase in the concentration of cardiac glycosides in the blood plasma and the risk of developing glycoside intoxication are possible.

When used simultaneously with disopyramide, a case of development of ventricular fibrillation has been described.

When used simultaneously with lovastatin, cases of rhabdomyolysis have been described.

When used simultaneously with rifabutin, the risk of developing neutropenia and leukopenia increases.

With simultaneous use, the metabolism of cyclosporine is disrupted, which increases the risk of developing adverse and toxic reactions caused by cyclosporine.

Manufacturer

Ozon, Russia